Veru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones
20 avr. 2023 06h45 HE
|
Veru Inc.
MIAMI, FL, April 20, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for oncology and SARS-CoV-2 and other viral ARDS-related...
Veru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 Female Condom® in U.S. Public Health Sector
19 avr. 2023 08h30 HE
|
Veru Inc.
MIAMI, FL, April 19, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for oncology and SARS-CoV-2 and other viral ARDS-related...
Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses
11 avr. 2023 08h30 HE
|
Veru Inc.
Sabizabulin inhibited the cell release and cell-to-cell spread of poxvirus in a preclinical study Veru further expands study of sabizabulin for the treatment of poxvirus acute respiratory distress...
Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 Program
04 avr. 2023 08h30 HE
|
Veru Inc.
In the final report, sabizabulin significantly reduced key cytokines involved in Acute Respiratory Distress Syndrome (ARDS) in H1N1 influenza pulmonary inflammation murine ARDS model Positive...
Veru to Present at the Oppenheimer 33rd Annual Healthcare Conference
07 mars 2023 08h30 HE
|
Veru Inc.
MIAMI, FL., March 07, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for...
Veru Provides FDA Update on Request for Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for ARDS
02 mars 2023 16h01 HE
|
Veru Inc.
MIAMI, FL, March 02, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for...
Veru Reports Fiscal 2023 First Quarter Financial Results
09 févr. 2023 06h30 HE
|
Veru Inc.
Sabizabulin for moderate to severe COVID-19 under review for potential emergency authorization by multiple global regulatory agencies Presented late-breaker oral presentation at IDWeek; sabizabulin...
Veru to Report Fiscal 2023 First Quarter Financial Results on February 9, 2023
26 janv. 2023 08h30 HE
|
Veru Inc.
MIAMI, FL, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for...
Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board
10 janv. 2023 08h30 HE
|
Veru Inc.
MIAMI. FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for...
Veru Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results
05 déc. 2022 06h30 HE
|
Veru Inc.
U.S. FDA reviewing EUA application for sabizabulin to treat hospitalized COVID-19 patients at high risk for ARDS European Medicines Agency’s (EMA) Emergency Task Force reviewing sabizabulin for...